Trial Profile
The Use of a Long Acting GnRH Antagonist (Degarelix) in Controlled Ovarian Hyperstimulation in PCOS Women at a Risk to Developing OHSS Undergoing IVF : a Pilot Study
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Ovarian hyperstimulation syndrome; Polycystic ovary syndrome
- Focus Therapeutic Use
- 27 Jun 2014 New trial record